Neuroendocrine tumors are rare epithelial neoplasms with neuroendocrine differentiation that most commonly originate in the lungs and gastrointestinal tract.  Many patients have advanced disease not amenable to surgery or local management. Some tumors also secrete peptides, such as serotonin, that lead to syndromes of hormone excess, such as diarrhea and flushing.  Thus, management of patients with neuroendocrine tumors often requires a dual approach including hormone symptom management and systemic tumor control.  Somatostatin analogues have long been a mainstay of managing the hormone-related symptoms.  There is also increasing evidence for the use of somatostatin analogues for tumor control in patients with well-differentiated neuroendocrine tumors.  This article will review the role of somatostatin analogues in the treatment of NETs.